

Immediate versus deferred treatment for advanced pro Medical Research Council trial

British Journal of Urology

79, 235-246

DOI: [10.1046/j.1464-410x.1997.d01-6840.x](https://doi.org/10.1046/j.1464-410x.1997.d01-6840.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer – The Therapeutic Challenge of Locally Advanced Disease. <i>New England Journal of Medicine</i> , 1997, 337, 340-341.	13.9	6
2	Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials. <i>Urology</i> , 1997, 49, 39-45.	0.5	8
3	Prostate cancer. <i>Lancet, The</i> , 1997, 349, 1552.	6.3	2
4	Early prostate cancer-to treat or not to treat?. <i>Lancet, The</i> , 1997, 349, 892-893.	6.3	21
5	MRC study: when to commence treatment in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 1997, 1, 11-15.	2.0	13
6	Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing Components. <i>International Journal of Urology</i> , 1998, 5, 303-311.	0.5	8
7	Intermittent androgen suppression for prostate cancer: rationale and clinical experience. <i>Prostate Cancer and Prostatic Diseases</i> , 1998, 1, 289-296.	2.0	51
8	Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit?. <i>Seminars in Radiation Oncology</i> , 1998, 8, 95-106.	1.0	23
11	Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer?. <i>BJU International</i> , 1998, 81, 87-95.	1.3	11
12	Prostate cancer: how aware is the public?. <i>BJU International</i> , 1998, 82, 43-48.	1.3	32
13	The management of locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1998, 4, 3-12.	0.8	22
14	Prostate cancer in the elderly. <i>European Journal of Surgical Oncology</i> , 1998, 24, 379-383.	0.5	12
15	Evaluation and management of men whose radical prostatectomies failed: results of an international survey. <i>Urology</i> , 1998, 52, 1047-1054.	0.5	75
16	EVALUATION AND MANAGEMENT OF THE MAN WHO HAS FAILED PRIMARY CURATIVE THERAPY FOR PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1998, 25, 591-601.	0.8	26
17	RE: IMMEDIATE VERSUS DEFERRED TREATMENT FOR ADVANCED PROSTATE CANCER: INITIAL RESULTS OF THE MEDICAL RESEARCH COUNCIL TRIAL (EDITORIAL COMMENT). <i>Journal of Urology</i> , 1998, 159, 2105-2105.	0.2	1
18	COMBINED ORCHIECTOMY AND EXTERNAL RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR NONMETASTATIC PROSTATE CANCER WITH OR WITHOUT PELVIC LYMPH NODE INVOLVEMENT: A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Urology</i> , 1998, 159, 2030-2034.	0.2	208
19	Perineal Seeding of Prostate Cancer as the Only Evidence of Clinical Recurrence 14 Years After Needle Biopsy and Radical Prostatectomy: Molecular Correlation. <i>Urology</i> , 1998, 51, 158-160.	0.5	28
20	Intermittent Androgen Deprivation for Clinically Localized Prostate Cancer: Initial Experience. <i>Urology</i> , 1998, 51, 137-144.	0.5	71

#	ARTICLE	IF	CITATIONS
21	Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. <i>Urology</i> , 1998, 52, 1094-1097.	0.5	20
22	Treatment options for early prostate cancer. <i>Urology</i> , 1998, 52, 948-962.	0.5	39
23	The management of PSA failure after radical radiotherapy for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 1998, 49, 103-110.	0.3	34
24	Prostate Cancer. <i>Drugs and Aging</i> , 1998, 13, 71-81.	1.3	21
25	All changed, changed utterly. <i>BMJ: British Medical Journal</i> , 1998, 316, 1917-1918.	2.4	259
26	Diseases of the prostate. <i>Reviews in Clinical Gerontology</i> , 1998, 8, 15-22.	0.5	0
27	Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer. <i>Cancer Control</i> , 1998, 5, 513-521.	0.7	11
28	Management of metastatic prostate cancer. <i>Medical Journal of Australia</i> , 1998, 169, 46-50.	0.8	12
29	Therapeutic Dilemmas in Prostate Cancer: Justification for Watchful Waiting. <i>European Urology</i> , 1998, 34, 33-36.	0.9	15
30	Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience. <i>European Urology</i> , 1998, 34, 37-41.	0.9	81
31	The Natural History of Early Prostate Cancer and the Impact of Endocrine Treatment. <i>European Urology</i> , 1999, 36, 3-8.	0.9	8
32	Early versus Deferred Hormone Therapy. <i>European Urology</i> , 1999, 36, 9-13.	0.9	9
33	The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks. <i>European Urology</i> , 1999, 36, 27-30.	0.9	1
34	Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?. <i>Journal of Clinical Oncology</i> , 1999, 17, 3664-3675.	0.8	36
35	Prostate Cancer Management Under Scrutiny: One Man's Meta-Analysis Is Another Man's Poisson. <i>Journal of Clinical Oncology</i> , 1999, 17, 3371-3373.	0.8	3
36	Recent advances in the treatment of prostate cancer. <i>Annals of Oncology</i> , 1999, 10, 891-898.	0.6	27
37	Early Androgen Deprivation for Prostate Cancer?. <i>New England Journal of Medicine</i> , 1999, 341, 1837-1838.	13.9	75
38	Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer. <i>New England Journal of Medicine</i> , 1999, 341, 1781-1788.	13.9	1,154

#	ARTICLE	IF	CITATIONS
39	Follow-up costs after external radiation for low risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 1999, 44, 323-326.	0.4	11
40	Treatment of prostate cancer. Journal of Clinical Pharmacy and Therapeutics, 1999, 24, 93-102.	0.7	47
41	Combined androgen blockade for advanced prostatic carcinoma. Prostate Cancer and Prostatic Diseases, 1999, 2, 172-179.	2.0	13
42	Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Quality of Life Research, 1999, 8, 461-470.	1.5	24
43	Finally, good news about prostate carcinoma in African American men. , 1999, 86, 1-2.		1
44	Adherence by African American men to prostate cancer education and early detection. , 1999, 86, 88-104.		82
45	DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. Journal of Urology, 1999, 161, 1189-1191.	0.2	50
46	Prostate Cancer Registration in Four Swedish Regions 1996: Differences in Incidence, Age Structure and Management. Scandinavian Journal of Urology and Nephrology, 1999, 33, 306-311.	1.4	12
47	Current status of androgen suppression and radiotherapy for patients with prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 239-245.	1.2	7
48	Overview: hormone refractory prostate cancer. Urology, 1999, 54, 1-7.	0.5	77
50	DEFERRED TREATMENT OF LOCALLY ADVANCED NONMETASTATIC PROSTATE CANCER: A LONG-TERM FOLLOWUP. Journal of Urology, 1999, 161, 505-508.	0.2	34
51	PROSTATE CANCER. Medical Clinics of North America, 1999, 83, 1231-1245.	1.1	8
52	Intermittent androgen suppression in the management of prostate cancer. Urology, 1999, 53, 530-534.	0.5	112
53	Screening and treatment of localized prostate cancer decreases mortality: First analysis of the first prospective and randomized study on prostate cancer screening. Aging Male, 1999, 2, 33-43.	0.9	6
54	Hormonal Therapy for Advanced Prostate Cancer. Annals of Internal Medicine, 2000, 132, 584.	2.0	5
55	Common urologic problems in the elderly. Postgraduate Medicine, 2000, 107, 163-178.	0.9	7
56	The timing of hormonal treatment for prostate cancer. Current Opinion in Urology, 2000, 10, 403-407.	0.9	0
57	Prostate carcinoma trends in three counties in Sweden 1987-1996. , 2000, 88, 1445-1453.		32

#	ARTICLE	IF	CITATIONS
58	Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. <i>Prostate</i> , 2000, 43, 215-222.	1.2	34
59	Endocrine treatment in prostate cancer. , 2000, 18, 52-74.		145
60	Prostate cancer screening. <i>Microscopy Research and Technique</i> , 2000, 51, 419-422.	1.2	1
61	Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. <i>Prostate</i> , 2000, 45, 19-35.	1.2	64
62	The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. <i>Cancer</i> , 2000, 88, 2989-2994.	2.0	334
63	Hormone therapy for patients with prostate carcinoma. <i>Cancer</i> , 2000, 88, 3009-3014.	2.0	96
64	Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. <i>BJU International</i> , 2000, 85, 1078-1084.	1.3	57
65	Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 35, 121-132.	2.0	25
66	Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 617-627.	0.4	170
67	Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 609-615.	0.4	166
68	The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 153-158.	0.4	28
69	Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2000, 3, 286-289.	2.0	2
70	Immediate hormonal therapy after surgery for node-positive prostate cancer improves survival and disease-free recurrence. <i>Evidence-based Oncology</i> , 2000, 1, 77-78.	0.1	0
71	Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 385-390.	1.7	12
72	Prostate cancer treated by anti-androgens: is sexual function preserved?. <i>British Journal of Cancer</i> , 2000, 82, 283-290.	2.9	81
73	Immediate vs. delayed androgen deprivation for prostate cancer. <i>Prostate</i> , 2000, 45, 19-25.	1.2	51
74	Endocrine treatment: Expected duration stage by stage. <i>Prostate</i> , 2000, 45, 26-31.	1.2	3
75	Adjuvant Chemo-/Hormonal Therapy Trials for Locally Advanced Prostate Cancer. <i>Current Oncology Reports</i> , 2000, 2, 402-408.	1.8	4

#	ARTICLE	IF	CITATIONS
76	Intermittent androgen deprivation. <i>Current Oncology Reports</i> , 2000, 2, 409-416.	1.8	14
77	What does prostate-specific antigen recurrence mean?. <i>Current Urology Reports</i> , 2000, 1, 28-35.	1.0	9
78	Quality of life following prostate cancer treatments. <i>Current Urology Reports</i> , 2000, 1, 71-77.	1.0	6
79	Medikamentöse Therapie des hormonsensiblen und hormonresistenten Prostatakarzinoms. <i>Onkologie</i> , 2000, 6, 137-143.	0.7	1
80	Radiation Endocrine Action in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 4004-4005.	0.8	0
81	Standard Chemotherapy for Gastric Carcinoma: Is It a Myth?. <i>Journal of Clinical Oncology</i> , 2000, 18, 4001-4003.	0.8	43
82	Why Stop at Using High-Dose-Rate Brachytherapy as a Boost for the Prostate?. <i>Journal of Clinical Oncology</i> , 2000, 18, 4003-4004.	0.8	1
83	Breast Cancer Radiotherapy: Safe for All?. <i>Journal of Clinical Oncology</i> , 2000, 18, 4000-4001.	0.8	8
84	Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. <i>British Journal of Cancer</i> , 2000, 83, 443-446.	2.9	67
85	Early Hormonal Therapy in Prostate Cancer. <i>New England Journal of Medicine</i> , 2000, 342, 1215-1216.	13.9	4
87	Management of Advanced Prostate Cancer. <i>Oncologist</i> , 2000, 5, 36-44.	1.9	61
88	PSA doubling times. <i>Lancet Oncology</i> , The, 2000, 1, 14-15.	5.1	1
89	Trends in prostate cancer mortality in England, Wales, and the USA. <i>Lancet Oncology</i> , The, 2000, 1, 14.	5.1	6
90	Eradication of a disease: how we cured asymptomatic prostate cancer. <i>Lancet Oncology</i> , The, 2000, 1, 17-19.	5.1	59
91	Patient-Clinician Choice in Palliation of Metastatic Prostate Cancer. <i>Drugs and Aging</i> , 2000, 17, 331-337.	1.3	1
92	Follow-up of Prostate Cancer Patients by On-demand Contacts with a Specialist Nurse: A Randomized Study. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 55-61.	1.4	64
93	PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 163, 1632-1642.	0.2	305
94	QUALITY OF LIFE OF ASYMPTOMATIC MEN WITH NONMETASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY. <i>Journal of Urology</i> , 2000, 163, 1743-1746.	0.2	228

#	ARTICLE	IF	CITATIONS
95	EAU Guidelines on Prostate Cancer. <i>European Urology</i> , 2001, 40, 97-101.	0.9	92
96	Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. <i>The Cochrane Library</i> , 2001, , CD003506.	1.5	63
97	A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT. <i>Journal of Urology</i> , 2001, 166, 508-516.	0.2	100
98	The bicalutamide Early Prostate Cancer Program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2001, 6, 43-47.	0.8	63
99	Androgen antagonists: Potential role in prostate cancer prevention. <i>Urology</i> , 2001, 57, 64-67.	0.5	19
100	Perspectives on prostate cancer diagnosis and treatment: a roundtable. <i>Urology</i> , 2001, 58, 135-140.	0.5	6
101	Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. <i>Urology</i> , 2001, 58, 146-150.	0.5	76
102	Early versus late androgen deprivation therapy in metastatic disease. <i>Urology</i> , 2001, 58, 50-55.	0.5	9
103	Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. <i>Urology</i> , 2001, 58, 56-64.	0.5	28
104	Molecular prediction of progression in patients with conservatively managed prostate cancer. <i>Urology</i> , 2001, 58, 762-766.	0.5	12
105	SALVAGE RADICAL PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 2001, 28, 545-553.	0.8	38
106	Advanced Prostate Cancer: Immediate or Deferred Hormone Therapy?. <i>European Urology</i> , 2001, 39, 15-21.	0.9	12
107	Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?. <i>European Urology</i> , 2001, 39, 22-28.	0.9	21
108	Early versus Deferred Hormonal Treatment for Asymptomatic Prostate Cancer. <i>Oncology Research and Treatment</i> , 2001, 24, 214-220.	0.8	2
109	Active Monitoring (Deferred Treatment or Watchful Waiting) in the Treatment of Prostate Cancer. <i>European Urology</i> , 2001, 40, 488-494.	0.9	19
110	Hormone Therapy in Prostate Cancer. <i>Tumori</i> , 2001, 87, 52-53.	0.6	0
111	An update on prostate cancer. <i>Current Opinion in Oncology</i> , 2001, 13, 204-211.	1.1	12
112	Serum PSA Evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1220-1225.	0.4	14

#	ARTICLE	IF	CITATIONS
113	Lack of prostate cancer radiosensitization by androgen deprivation. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1002-1007.	0.4	70
114	Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU International, 2001, 83, 161-170.	1.3	52
116	Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. BJU International, 2001, 85, 699-704.	1.3	17
117	The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU International, 2001, 86, 181-190.	1.3	7
118	Patient self-injection: a new approach to administering luteinizing hormone-releasing hormone analogues. BJU International, 2001, 86, 840-842.	1.3	10
119	Treatment options after failure of local curative treatments in prostate cancer: a controversial issue. BJU International, 2001, 86, 1014-1022.	1.3	10
120	New therapeutic concepts in prostate cancer. BJU International, 2001, 88, 43-48.	1.3	12
121	Radical radiation therapy options for organ-confined prostate cancer. BJU International, 2001, 87, 431-440.	1.3	0
122	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. Cancer, 2001, 91, 2175-2180.	2.0	7
123	International trends in prostate-cancer mortality in the ?PSA era?. International Journal of Cancer, 2001, 92, 893-898.	2.3	150
124	The Treatment of Prostate Cancer. . An Overview of Current Options. Cancer Practice, 2001, 9, 295-306.	0.8	46
125	Advancing Perspectives on Prostate Cancer: Multihormonal Influences in Pathogenesis. Molecular Urology, 2001, 5, 181-188.	1.0	4
126	Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2001, 345, 948-955.	13.9	669
127	Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients. Oncologist, 2001, 6, 177-182.	1.9	56
128	Perspectives in Adjuvant Treatment of Prostate Cancer. Urologia Internationalis, 2002, 68, 1-5.	0.6	3
129	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 599-603.	1.8	597
130	Prostate cancer: management of advanced disease. Annals of Oncology, 2002, 13, 89-94.	0.6	9
131	An investigation into the use of palliative care services by patients with prostate cancer. American Journal of Hospice and Palliative Medicine, 2002, 19, 259-262.	0.8	6

#	ARTICLE	IF	CITATIONS
132	Hormone Therapy in Advanced Prostate Cancer. , 2002, 36, 49-65.		5
133	Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137, 917.	2.0	298
134	Background to and Management of Treatment-Related Bone Loss in Prostate Cancer. Drugs and Aging, 2002, 19, 899-910.	1.3	17
135	An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 1313-1328.	0.9	82
136	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program. Journal of Urology, 2002, 168, 429-435.	0.2	206
137	Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2002, 167, 1952-1956.	0.2	153
138	Hormonal therapy for prostate cancer: past, present and future. Expert Review of Anticancer Therapy, 2002, 2, 37-47.	1.1	15
139	Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology, 2002, 60, 22-30.	0.5	14
140	Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology, 2002, 60, 120-124.	0.5	43
141	Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology, 2002, 60, 201-208.	0.5	83
142	Hormonal therapy for prostate cancer: primum non nocere. Urology, 2002, 60, 738-741.	0.5	11
143	Timing of androgen deprivation for prostate cancer: benefits versus side effectsâ€”a patient-physician dialogue. Urology, 2002, 60, 735-737.	0.5	11
144	Eradication of a disease: how we cured symptomless prostate cancer. Lancet, The, 2002, 359, 1341-1342.	6.3	29
145	Patient Selection for Therapy in Prostate Cancer. European Urology Supplements, 2002, 1, 2-6.	0.1	0
146	PSAâ€™Promoter of Stress and Anxiety or Providentially-Sent Antigen?. European Urology Supplements, 2002, 1, 10-14.	0.1	3
147	Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (â€”Casodexâ€™) EPC Programme. European Urology Supplements, 2002, 1, 20-25.	0.1	3
148	How Do We Deal with Rising PSA after Primary Therapy?. European Urology Supplements, 2002, 1, 33-38.	0.1	0
149	Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treatment Reviews, 2002, 28, 189-194.	3.4	4

#	ARTICLE	IF	CITATIONS
150	Hormone Therapy for Locally Advanced Prostate Cancer. <i>Journal of Urology</i> , 2002, 168, 546-549.	0.2	48
151	Timing hormonal therapy in prostate cancer. <i>Urologic Clinics of North America</i> , 2002, 29, 223-227.	0.8	3
152	Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer. <i>Journal of Urology</i> , 2002, 168, 1005-1007.	0.2	318
153	RE: A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT (letter to the editor). <i>Journal of Urology</i> , 2002, 168, 2131-2131.	0.2	0
154	RE: A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT. <i>Journal of Urology</i> , 2002, 167, 651-652.	0.2	6
158	Controversies Surrounding Androgen Deprivation for Prostate Cancer. <i>Cancer Control</i> , 2002, 9, 315-325.	0.7	13
159	The Current State of Hormonal Therapy for Prostate Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 154-179.	157.7	323
160	A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Group Study No. 6. <i>European Urology</i> , 2002, 42, 204-211.	0.9	47
161	Should we start population screening for prostate cancer? Randomised trials are still needed. <i>International Journal of Cancer</i> , 2002, 97, 377-378.	2.3	16
162	Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation. <i>Cancer</i> , 2002, 94, 1648-1653.	2.0	9
163	Follow-up surveillance strategies for genitourinary malignancies. <i>Cancer</i> , 2002, 94, 2892-2905.	2.0	17
164	The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. <i>Cancer</i> , 2002, 95, 287-295.	2.0	103
165	The use of bisphosphonates in the management of bone metastatic prostate cancer. <i>Current Urology Reports</i> , 2002, 3, 244-249.	1.0	2
166	The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 179-188.	2.0	5
167	EORTC prostate cancer trials: what have we learnt?. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 159-165.	2.0	2
168	Practical application of biochemical failure definitions: what to do and when to do it. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 304-315.	0.4	74
169	Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1152-1159.	0.4	4
170	Initiation of salvage therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2002, 5, 136-143.	2.0	9

#	ARTICLE	IF	CITATIONS
171	The potential role of bisphosphonates in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2002, 5, 264-272.	2.0	52
172	Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 107-118.	0.4	25
173	Early or delayed hormonal therapy in N+ M+ disease. <i>Current Problems in Cancer</i> , 2003, 27, 49-52.	1.0	0
174	Quality of life after treatment for prostate cancer. <i>Current Prostate Reports</i> , 2003, 1, 55-65.	0.1	1
175	Quality of life after treatment for prostate cancer. <i>Current Urology Reports</i> , 2003, 4, 185-195.	1.0	61
176	Radiotherapy for T3 prostate cancer. <i>Current Urology Reports</i> , 2003, 4, 205-210.	1.0	2
177	Treatment of prostate cancer with regional lymph node (N1) metastasis. <i>Seminars in Radiation Oncology</i> , 2003, 13, 121-129.	1.0	11
178	Radiation therapy after radical prostatectomy: A review of the issues and options. <i>Seminars in Radiation Oncology</i> , 2003, 13, 130-140.	1.0	42
179	PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millenium. <i>European Urology</i> , 2003, 43, 12-27.	0.9	73
180	A 10-Year Clinical Experience with Intermittent Hormonal Therapy for Prostate Cancer. <i>European Urology</i> , 2003, 43, 233-240.	0.9	64
181	The Impact of Androgen Deprivation Therapy on Health Related Quality of Life in Asymptomatic Men with Lymph Node Positive Prostate Cancer. <i>European Urology</i> , 2003, 44, 209-214.	0.9	50
182	An evidence-based approach to prostate cancer follow-up. <i>Seminars in Oncology</i> , 2003, 30, 390-400.	0.8	9
183	Prostate carcinoma. <i>Cancer</i> , 2003, 97, 758-771.	2.0	45
184	High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. <i>Cancer</i> , 2003, 97, 1217-1224.	2.0	120
185	Trends in prostate cancer mortality among black men and white men in the United States. <i>Cancer</i> , 2003, 97, 1507-1516.	2.0	170
186	Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma. <i>Cancer</i> , 2003, 98, 2351-2361.	2.0	18
187	The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer. <i>International Journal of Cancer</i> , 2003, 103, 91-96.	2.3	11
188	Biochemical recurrence of prostate cancer. <i>Current Problems in Cancer</i> , 2003, 27, 243-272.	1.0	5

#	ARTICLE	IF	CITATIONS
189	What to do for prostate cancer patients with a rising PSA?â€”a survey of Australian practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 986-991.	0.4	27
190	Metastatic Prostate Cancer: Complications and Treatment. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1136-1142.	1.3	44
191	Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias. <i>BJU International</i> , 2003, 91, 9-13.	1.3	7
192	Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?. <i>BJU International</i> , 2003, 91, 613-617.	1.3	22
193	Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom scores. <i>BJU International</i> , 2003, 91, 795-797.	1.3	35
194	Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. <i>BJU International</i> , 2003, 92, 690-694.	1.3	77
195	Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 51-63.	0.4	52
196	Biochemical failure after definitive therapy of prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 859-860.	0.4	8
197	Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 11-18.	0.4	87
198	Recurrent prostate cancer following external beam radiotherapy. <i>Urologic Clinics of North America</i> , 2003, 30, 751-763.	0.8	27
199	Follow-up of conservatively managed prostate cancer. <i>Urologic Clinics of North America</i> , 2003, 30, 687-702.	0.8	14
200	The Management of High Risk Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 1993-1998.	0.2	23
201	Prostate cancer: radical prostatectomy. <i>Urologic Clinics of North America</i> , 2003, 30, 703-723.	0.8	20
202	Selecting a secondary treatment. <i>Urologic Clinics of North America</i> , 2003, 30, 403-414.	0.8	0
203	The Nonsteroidal Effects of Diethylstilbestrol: The Rationale for Androgen Deprivation Therapy Without Estrogen Deprivation in the Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2003, 170, 1703-1708.	0.2	62
204	The physical burden of prostate cancer. <i>Urologic Clinics of North America</i> , 2003, 30, 305-313.	0.8	34
206	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. <i>Urology</i> , 2003, 62, 147-154.	0.5	12
207	Exploring the effects of luteinizing hormoneâ€”releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. <i>Urology</i> , 2003, 62, 29-35.	0.5	11

#	ARTICLE	IF	CITATIONS
208	Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. <i>Urology</i> , 2003, 62, 20-28.	0.5	56
209	Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. <i>Urology</i> , 2003, 62, 36-42.	0.5	23
210	Variables in predicting survival based on treating "PSA-Only" relapse. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 292-304.	0.8	42
211	Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. <i>Urology</i> , 2003, 61, 380-385.	0.5	24
212	Early versus late hormonal therapy: debating the issues. <i>Urology</i> , 2003, 61, 8-13.	0.5	11
213	National Comprehensive Cancer Network guidelines for the management of prostate cancer. <i>Urology</i> , 2003, 61, 14-24.	0.5	152
214	Effective testosterone suppression for patients with prostate cancer: is there a best castration?. <i>Urology</i> , 2003, 62, 207-213.	0.5	43
215	Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. <i>Urology</i> , 2003, 62, 872-876.	0.5	29
216	How Should We Treat Patients with Locally Advanced Prostate Cancer?. <i>European Urology Supplements</i> , 2003, 2, 14-22.	0.1	4
218	The timing of hormone therapy for men with asymptomatic advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 245-254.	0.8	19
219	High-risk localized prostate cancer: primary surgery and adjuvant therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 219-227.	0.8	19
220	The truth is out there: an overall perspective on androgen deprivation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 272-281.	0.8	12
221	Treatment of Prostate Cancer—The Role of Primary Hormonal Therapy. <i>EAU Update Series</i> , 2003, 1, 32-39.	0.5	10
222	Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer. <i>Drugs and Aging</i> , 2003, 20, 115-124.	1.3	4
223	Metastatic Prostate Cancer. <i>American Journal of Cancer</i> , 2003, 2, 87-94.	0.4	0
224	Clinical Approaches to Osseous Metastases in Prostate Cancer. <i>Oncologist</i> , 2003, 8, 161-173.	1.9	32
225	Prostate cancer management: (2) an update on locally advanced and metastatic disease. <i>Postgraduate Medical Journal</i> , 2003, 79, 643-645.	0.9	18
226	National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 981-989.	3.0	323

#	ARTICLE	IF	CITATIONS
227	The Prostate Cancer Conundrum. Journal of the National Cancer Institute, 2003, 95, 930-931.	3.0	15
228	The rationale for adjuvant chemotherapy for high-risk prostate cancer. Current Opinion in Urology, 2003, 13, 123-131.	0.9	2
229	Cancer of the Prostate. , 0, , 354-359.		1
231	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. Tumori, 2004, 90, 535-546.	0.6	34
232	Biochemical failure as single abnormality in patients with prostate cancer following radical treatment with external radiotherapy: follow-up without immediate treatment. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2004, 30, 289-295.	0.7	1
233	American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2927-2941.	0.8	167
234	Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88. Journal of Clinical Oncology, 2004, 22, 4109-4118.	0.8	87
235	The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. Journal of Clinical Oncology, 2004, 22, 2141-2149.	0.8	528
236	Diseases of the prostate. Reviews in Clinical Gerontology, 2004, 14, 119-128.	0.5	0
237	Long-Term Outcomes in Patients with Prostate Cancer Managed with Intermittent Androgen Suppression. Urologia Internationalis, 2004, 73, 117-122.	0.6	36
238	Prostate cancer management. Annals of Oncology, 2004, 15, iv307-iv312.	0.6	6
239	Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?. BJU International, 2004, 93, 695-701.	1.3	22
240	Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. BJU International, 2004, 93, 845-850.	1.3	8
241	State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU International, 2004, 94, 268-271.	1.3	33
242	Intermittent androgen suppression. BJU International, 2004, 93, 258-261.	1.3	19
243	More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer. BJU International, 2004, 93, 1175-1176.	1.3	8
244	Proteomics and urine analysis: a potential promising new tool in urology. BJU International, 2004, 93, 1172-1173.	1.3	17
245	The ethics of rewarded kidney donation. BJU International, 2004, 93, 1171-1172.	1.3	4

#	ARTICLE	IF	CITATIONS
246	The 'learning curve' in surgery: what is it, how do we measure it and can we influence it?. BJU International, 2004, 93, 1173-1174.	1.3	104
247	Biochemical failure: role for early hormonal therapy. BJU International, 2004, 94, 9-10.	1.3	2
248	Hormonal treatment alone for locally advanced prostate cancer. BJU International, 2004, 94, 14-15.	1.3	6
249	Combined androgen blockade in the management of advanced prostate cancer: A sensible or ostensible approach. International Journal of Urology, 2004, 11, 1092-1096.	0.5	6
250	Management of recurrent disease after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2004, 7, 211-216.	2.0	85
251	Timing and choice of androgen ablation. Prostate Cancer and Prostatic Diseases, 2004, 7, 217-222.	2.0	29
252	Genitourinary cancer in the elderly. Seminars in Oncology, 2004, 31, 249-263.	0.8	7
253	A Vaccination Strategy for the Long-Term Suppression of Androgens in Advanced Prostate Cancer. European Urology, 2004, 45, 171-175.	0.9	19
254	Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal of Bone and Mineral Research, 2004, 19, 1766-1770.	3.1	43
256	Potential survival advantage with early androgen deprivation for biochemical failure after external beam radiotherapy: The importance of accurately defining biochemical disease status. International Journal of Radiation Oncology Biology Physics, 2004, 60, 453-462.	0.4	7
257	Early versus late hormonal therapy for prostate cancer. Current Prostate Reports, 2004, 2, 60-68.	0.1	0
258	Early versus late hormonal therapy for prostate cancer. Current Urology Reports, 2004, 5, 188-196.	1.0	6
259	Interest in services among prostate cancer patients receiving androgen deprivation therapy. Psycho-Oncology, 2004, 13, 512-525.	1.0	28
260	Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate, 2004, 59, 311-318.	1.2	176
261	Intervention after PSA failure: Examination of intervention time and subsequent outcomes from a prospective patient database. International Journal of Radiation Oncology Biology Physics, 2004, 60, 463-469.	0.4	37
262	EARLY VERSUS DELAYED ENDOCRINE TREATMENT OF pN1-3 M0 PROSTATE CANCER WITHOUT LOCAL TREATMENT OF THE PRIMARY TUMOR: RESULTS OF EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER 30846â€”A PHASE III STUDY. Journal of Urology, 2004, 172, 923-927.	0.2	95
263	BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6. Journal of Urology, 2004, 172, 1871-1876.	0.2	95
264	Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urologic Clinics of North America, 2004, 31, 331-352.	0.8	69

#	ARTICLE	IF	CITATIONS
265	TRANSDERMAL ESTRADIOL IMPROVES BONE DENSITY WHEN USED AS SINGLE AGENT THERAPY FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2004, 172, 2203-2207.	0.2	46
266	Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Urology</i> , 2004, 171, 1141-1147.	0.2	226
267	Management of Prostate Cancer. , 2004, , .		2
268	Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. <i>Urology</i> , 2004, 64, 1171-1176.	0.5	89
269	PSA relapse prostate cancer: the importance of tailored therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 62-69.	0.8	9
270	Endocrine treatment of prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004, 92, 287-295.	1.2	84
272	Hormonal therapy in cancer. <i>Medicine</i> , 2004, 32, 30-32.	0.2	2
274	Re: Vikram, B., The PSA conundrum. <i>Radiother Oncol</i> , 2004. 71(1): p. 1â€“2. <i>Radiotherapy and Oncology</i> , 2004, 73, 252-254.	0.3	1
275	How the Addition of Hormones Improves Outcome: Hormone Therapy Alone in Locally Advanced Prostate Cancer. <i>European Urology Supplements</i> , 2004, 3, 22-26.	0.1	0
276	The Emerging Role of Bisphosphonates in Prostate Cancer. <i>American Journal of Therapeutics</i> , 2004, 11, 60-73.	0.5	4
277	Is There a â€œCurativeâ€•Role of Radiotherapy for Clinically Localized Hormone Refractory Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 264-268.	0.6	15
278	Title is missing!. <i>Radiotherapy and Oncology</i> , 2004, 73, 254-255.	0.3	1
279	Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*. <i>Current Opinion in Urology</i> , 2005, 15, 187-195.	0.9	21
280	Hormone therapy and radiotherapy for early prostate cancer: A utility-adjusted number needed to treat (NNT) analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 687-694.	0.4	9
281	Defining the Need for Local Therapy in Locally Advanced Prostate Cancer: An Appraisal of the MRC PR07 Study. <i>Clinical Oncology</i> , 2005, 17, 217-218.	0.6	7
282	Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. <i>BJU International</i> , 2005, 95, 285-290.	1.3	6
283	The 'flare' phenomenon: should we be concerned?. <i>BJU International</i> , 2005, 96, 4-6.	1.3	4
284	Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate. <i>European Urology</i> , 2005, 47, 575-581.	0.9	36

#	ARTICLE	IF	CITATIONS
285	Risks and Benefits of Hormonal Manipulation as Monotherapy or Adjuvant Treatment in Localised Prostate Cancer. <i>European Urology</i> , 2005, 48, 900-905.	0.9	23
286	Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in <i>Cancer</i> 2006;106(11):2530]. <i>Cancer</i> , 2005, 103, 237-241.	2.0	62
287	Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. <i>Cancer</i> , 2005, 103, 1615-1624.	2.0	309
288	Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. <i>Molecular Carcinogenesis</i> , 2005, 44, 1-10.	1.3	60
289	Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 47-57.	1.1	41
291	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	2.0	89
294	Regionally Advanced Adenocarcinoma of the Prostate (T3-4N+M0): Management and Prognosis. , 2005, , 494-504.		0
295	Metastatic Adenocarcinoma of the Prostate. , 2005, , 505-513.		0
296	The Vitality Index: Vital decisions in locally advanced prostate cancer. <i>NursePrescribing</i> , 2005, 3, S3-S7.	0.1	0
297	Endocrine therapy for prostate cancer. <i>Acta OncolÃ³gica</i> , 2005, 44, 605-609.	0.8	46
298	Long-term outcome of detectable PSA levels after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 163-166.	2.0	10
299	Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 140-151.	2.0	11
300	Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2918-2925.	0.8	430
301	Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate. <i>Journal of Clinical Oncology</i> , 2005, 23, 8225-8231.	0.8	60
302	Androgen Deprivation Therapy for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 238.	3.8	880
303	Locally advanced prostate cancer treated with radiotherapy and androgen deprivation. <i>Nature Reviews Urology</i> , 2005, 2, 304-308.	1.4	0
304	Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. <i>Nature Reviews Urology</i> , 2005, 2, 298-303.	1.4	4
305	Endocrine approaches in the therapy of prostate carcinoma. <i>Human Reproduction Update</i> , 2005, 11, 309-317.	5.2	21

#	ARTICLE	IF	CITATIONS
306	Rising prostate-specific antigen after primary prostate cancer therapy. <i>Nature Reviews Urology</i> , 2005, 2, 174-182.	1.4	84
307	Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7897-7903.	0.8	330
310	Immediate Treatment after PSA Progression. <i>European Urology Supplements</i> , 2005, 4, 28-42.	0.1	4
312	Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer. <i>European Urology Supplements</i> , 2005, 4, 4-13.	0.1	11
313	Optimising Hormone Therapy in Advanced Disease. <i>European Urology Supplements</i> , 2005, 4, 21-29.	0.1	10
314	Treatment of hormone sensitive prostate cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 331-338.	2.2	0
315	The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. <i>Clinical Therapeutics</i> , 2005, 27, 273-285.	1.1	4
316	An interdisciplinary approach to treating prostate cancer. <i>Urology</i> , 2005, 65, 13-18.	0.5	11
317	Treating the Biochemical Recurrence of Prostate Cancer After Definitive Primary Therapy. <i>Clinical Prostate Cancer</i> , 2005, 4, 38-44.	2.1	8
318	Cáncer de próstata. Tratamiento. <i>EMC - Urología</i> , 2005, 37, 1-24.	0.0	0
319	Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Group-6 Study after a median follow-up period of 7.1 years. <i>Scandinavian Journal of Urology and Nephrology</i> , 2006, 40, 441-452.	1.4	36
320	Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. <i>Lancet Oncology</i> , 2006, 7, 472-479.	5.1	803
321	Management of Hot Flashes in Men with Prostate Cancer Being Treated with Androgen Deprivation Therapy. <i>Supportive Cancer Therapy</i> , 2006, 4, 30-37.	0.3	7
322	High Risk Biochemical Relapse and the Timing of Androgen Deprivation Therapy. <i>Journal of Urology</i> , 2006, 176, S61-5.	0.2	9
323	Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2006, 176, 972-978.	0.2	117
324	Management of the Patient with a Rising PSA Alone. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 897-908.	0.9	5
325	Use of Hormonal Therapy in Men With Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2006, 176, 526-531.	0.2	19
326	Biochemical Recurrence after Localized Treatment. <i>Urologic Clinics of North America</i> , 2006, 33, 147-159.	0.8	21

#	ARTICLE	IF	CITATIONS
327	Mechanisms Leading to the Development of Hormone-Resistant Prostate Cancer. Urologic Clinics of North America, 2006, 33, 201-210.	0.8	53
328	The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose Parameters. Journal of Urology, 2006, 176, 520-525.	0.2	70
329	The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 2006, 176, S42-6.	0.2	1
330	Intermittent Androgen Deprivation: Clinical Experience and Practical Applications. Urologic Clinics of North America, 2006, 33, 167-179.	0.8	25
331	Cystectomy Delay More Than 3 Months From Initial Bladder Cancer Diagnosis Results in Decreased Disease Specific and Overall Survival. Journal of Urology, 2006, 175, 1262-1267.	0.2	168
332	Long-Term Followup of a Randomized Study of Locally Advanced Prostate Cancer Treated With Combined Orchiectomy and External Radiotherapy Versus Radiotherapy Alone. Journal of Urology, 2006, 176, 544-547.	0.2	80
333	Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. Clinical Therapeutics, 2006, 28, 1485-1508.	1.1	70
334	Genitourinary malignancies. Update on Cancer Therapeutics, 2006, 1, 443-466.	0.9	1
335	No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology, 2006, 67, 142-146.	0.5	12
337	Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 2006, 184, 176-179.	0.8	24
339	Evaluation of the Patient with Bone Metastases at Presentation. , 2006, , 545-554.		0
340	Application of three-dimensional fluoroscopic navigation in neural surgical operation. , 2006, , .		0
341	Can androgen deprivation be considered a primary treatment for prostate cancer?. Nature Reviews Urology, 2006, 3, 126-127.	1.4	0
342	Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion in Urology, 2006, 16, 173-178.	0.9	28
344	Apples and oranges. BJU International, 2006, 97, 435-438.	1.3	11
345	Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910.	1.3	2
346	Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU International, 2006, 98, 11-19.	1.3	12
347	The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU International, 2006, 98, 973-978.	1.3	83

#	ARTICLE	IF	CITATIONS
348	Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. <i>Asian Journal of Andrology</i> , 2006, 8, 555-561.	0.8	22
349	Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. <i>Current Oncology Reports</i> , 2006, 8, 213-220.	1.8	7
350	Primary hormone therapy for locally advanced prostate cancer. <i>Current Prostate Reports</i> , 2006, 4, 163-170.	0.1	0
351	Primary hormone therapy for locally advanced prostate cancer. <i>Current Urology Reports</i> , 2006, 7, 225-232.	1.0	1
352	Re: Immediate or Deferred Androgen Deprivation for Patients with Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. <i>European Urology</i> , 2006, 50, 384-385.	0.9	1
353	Evolving Role of Surgery, Radiation, Hormone Therapy, and Chemotherapy in High-Risk Locally Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 43-49.	0.9	5
354	Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out. <i>Nature Reviews Urology</i> , 2006, 3, 474-475.	1.4	1
355	Systemic treatment for prostate cancer. <i>Annals of Oncology</i> , 2006, 17, x211-x213.	0.6	1
356	Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4448-4456.	0.8	1,308
357	Timing of Androgen Deprivation Therapy: Some Questions Answered, Others Not. <i>Journal of the National Cancer Institute</i> , 2006, 98, 802-803.	3.0	4
358	How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2964-2964.	0.8	2
359	Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. <i>Journal of Clinical Oncology</i> , 2006, 24, 1868-1876.	0.8	313
360	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1685-1699.	0.9	6
361	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1639-1651.	1.1	3
362	Management of prostate cancer. Part 3: metastatic disease. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 813-821.	1.1	3
363	Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 552-563.	4.3	29
364	Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. <i>Cancer Biology and Therapy</i> , 2006, 5, 901-906.	1.5	50
365	Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2007, 10, 119-126.	2.0	8

#	ARTICLE	IF	CITATIONS
366	Medical Image Segmentation by Geodesic Active Contour Incorporating Region Statistical Information. , 2007, , .		8
367	Ophthalmoplegia â€“ an unusual manifestation of metastatic carcinoma of the prostate.. Scottish Medical Journal, 2007, 52, 53-53.	0.7	0
368	Reseach on Three-Dimensional Fluoroscopic Navigation in Neural Surgical Operation. , 2007, , .		0
369	Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology, 2007, 25, 1596-1605.	0.8	507
370	Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation. Urologia Internationalis, 2007, 79, 95-104.	0.6	5
371	Androgen deprivation therapy for prostate cancer: new concepts and concerns. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 247-254.	1.2	145
372	Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 101-109.	0.8	23
376	Hormone therapy for prostate cancer. European Journal of Cancer, Supplement, 2007, 5, 415-417.	2.2	0
377	Prostate Specific Antigen Recurrence After Definitive Therapy. Journal of Urology, 2007, 177, 1985-1991.	0.2	84
378	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
379	Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer. Pharmacoeconomics, 2007, 25, 309-327.	1.7	7
381	Hormonal Implications in the Development and Treatment of Prostate Cancer. Endocrinology and Metabolism Clinics of North America, 2007, 36, 421-434.	1.2	4
382	Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer. Journal of Urology, 2007, 177, 535-539.	0.2	15
383	Distilling the Past â€“ Envisioning the Future. , 2008, , 355-397.		0
384	Hormone Therapy For Prostate Cancer. , 2008, , 283-307.		0
386	Are prostatic biopsies necessary in men aged ?80i;½years?. BJU International, 2007, 99, 335-338.	1.3	11
387	Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU International, 2007, 99, 1383-1389.	1.3	32
388	Preventive effect of risedronate on bone loss in men receiving androgenâ€deprivation therapy for prostate cancer. International Journal of Urology, 2007, 14, 1071-1075.	0.5	34

#	ARTICLE	IF	CITATIONS
389	A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 323-328.	0.9	27
390	Additional Surgical Intervention after Radical Prostatectomy, Radiation Therapy, Androgen-Deprivation Therapy, or Watchful Waiting. <i>European Urology</i> , 2007, 52, 1036-1043.	0.9	27
391	Natural History of Biochemical Recurrence after Radical Prostatectomy: Risk Assessment for Secondary Therapy. <i>European Urology</i> , 2007, 51, 1175-1184.	0.9	222
392	Advances in the Treatment of Prostate Cancer. <i>Annual Review of Medicine</i> , 2007, 58, 205-220.	5.0	30
393	Optimal treatment of locally advanced prostate cancer. <i>World Journal of Urology</i> , 2007, 25, 169-176.	1.2	20
396	The spectrum of prostate cancer care: From curative intent to palliation. <i>Current Urology Reports</i> , 2007, 8, 245-252.	1.0	5
397	Current perspectives in the treatment of advanced prostate cancer. <i>Medical Oncology</i> , 2007, 24, 273-286.	1.2	13
399	The spectrum of prostate cancer care: From curative intent to palliation. <i>Current Prostate Reports</i> , 2008, 6, 56-63.	0.1	0
400	Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. <i>Cancer</i> , 2008, 112, 1247-1253.	2.0	107
401	Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary of JUA 2006 Edition). <i>International Journal of Urology</i> , 2008, 15, 1-18.	0.5	17
402	Use of androgen deprivation therapy for metastatic prostate cancer in older men. <i>BJU International</i> , 2008, 101, 1077-1083.	1.3	25
403	Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. <i>BMC Medicine</i> , 2008, 6, 6.	2.3	95
404	Local Progression among Men with Conservatively Treated Localized Prostate Cancer: Results from the Transatlantic Prostate Group. <i>European Urology</i> , 2008, 53, 347-354.	0.9	19
405	Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891). <i>European Urology</i> , 2008, 53, 941-949.	0.9	126
407	The benefits of early androgen blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 317-329.	2.2	5
409	Hormonal approaches in prostate cancer: Application in the contemporary prostate cancer patient. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 415-419.	0.8	16
410	The Treatment of Prostate Cancer.. <i>Cancer Practice</i> , 2001, 9, 295-306.	0.8	3
411	Estrategias terapéuticas del cáncer de próstata de estadio T3. <i>EMC - Urología</i> , 2008, 40, 1-11.	0.0	0

#	ARTICLE	IF	CITATIONS
412	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. European Urology Supplements, 2008, 7, 460-476.	0.1	4
413	Prostate cancer. Lancet, The, 2008, 371, 1710-1721.	6.3	421
415	Financial Consequences of Improved Treatments for Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2008, 19, 247-252.	0.2	1
416	Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Urology, 2008, 179, S53-9.	0.2	94
418	Androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 211-228.	0.9	72
419	Approach to the Prostate Cancer Patient with Bone Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2-7.	1.8	50
420	Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Review of Anticancer Therapy, 2008, 8, 269-281.	1.1	13
421	Hormone Therapy for Prostate Cancer – Immediate Initiation. , 2008, 41, 49-57.		2
422	Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2008, 300, 173.	3.8	274
425	Medical approach to advanced prostate cancer in older patients. Aging Health, 2008, 4, 481-494.	0.3	1
427	Hormones in cancer. , 0, , 23-38.		0
428	The “2-Week Wait” Rule for Referrals for Suspected Urological Cancers – Urgent Need for Refinement of Criteria. Annals of the Royal College of Surgeons of England, 2008, 90, 517-522.	0.3	16
429	Systemic therapy. , 0, , 93-101.		0
431	Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Therapeutics and Clinical Risk Management, 2008, Volume 4, 513-526.	0.9	24
432	Update on the management of prostate cancer with goserelin acetate: patient perspectives. Cancer Management and Research, 2009, Volume 1, 99-105.	0.9	0
433	Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 100-105.	0.8	104
434	Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2009, 12, 116-123.	2.0	7
435	Review: Risk stratification in the hormonal treatment of patients with prostate cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 79-94.	1.4	6

#	ARTICLE	IF	CITATIONS
436	Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0â€“4 N0â€“2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891). <i>Eur Urol</i> 2008;53:941â€“9. <i>European Urology</i> , 2009, 55, e43-e44.	0.9	0
437	Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks. <i>European Urology</i> , 2009, 55, 62-75.	0.9	139
438	The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer. <i>European Urology</i> , 2009, 56, 609-616.	0.9	54
439	Review of major adverse effects of androgenâ€“deprivation therapy in men with prostate cancer. <i>Cancer</i> , 2009, 115, 2388-2399.	2.0	268
440	Prostate cancer in senior adults: over- or undertreated?. <i>Wiener Medizinische Wochenschrift</i> , 2009, 159, 521-528.	0.5	3
441	A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. <i>World Journal of Urology</i> , 2009, 27, 627-635.	1.2	17
442	Management of locally advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 81-87.	0.8	13
443	Prostateâ€“specific antigenâ€“based screening for prostate cancer: Evidence, controversies and future perspectives. <i>International Journal of Urology</i> , 2009, 16, 458-464.	0.5	20
444	Longâ€“term changes in bone mineral density and predicted fracture risk in patients receiving androgenâ€“deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. <i>BJU International</i> , 2009, 104, 800-805.	1.3	92
445	Radiotherapy for patients with localized hormoneâ€“refractory prostate cancer: results of the Patterns of Care Study in Japan. <i>BJU International</i> , 2009, 104, 1462-1466.	1.3	14
446	Alendronate decreases the fracture risk in patients with prostate cancer on androgenâ€“deprivation therapy and with severe osteopenia or osteoporosis. <i>BJU International</i> , 2009, 104, 1637-1640.	1.3	36
447	Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. <i>Nature Reviews Urology</i> , 2009, 6, 76-85.	1.4	658
448	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 81-86.	0.8	31
449	A large proportion of patients with prostate cancer undergoing androgen deprivation therapy continue to die from non-cancer causes in the PSA era. <i>British Journal of Medical and Surgical Urology</i> , 2009, 2, 191-196.	0.2	1
450	Improving the Riskâ€“Benefit Ratio of Endocrine Therapy in Prostate Cancer. <i>European Urology Supplements</i> , 2009, 8, 108-113.	0.1	2
451	Treatment of local progression following radiotherapy. <i>European Journal of Cancer</i> , 2009, 45, 140-147.	1.3	0
452	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
453	Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 601-608.	0.2	129

#	ARTICLE	IF	CITATIONS
455	Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 240-246.	1.2	85
456	Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 162-200.	2.3	671
457	Synchronous testicular liposarcoma and prostate adenocarcinoma: a case report. <i>Cases Journal</i> , 2010, 3, 27.	0.4	10
458	Management of locally advanced prostate cancer. <i>Trends in Urology & Men's Health</i> , 2010, 1, 35-38.	0.2	0
459	Timing of Salvage Hormonal Therapy in Prostate Cancer Patients With Unfavorable Prognosis Treated With Radiotherapy: A Secondary Analysis of Radiation Therapy Oncology Group 85-31. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1301-1306.	0.4	23
460	Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. <i>Supportive Care in Cancer</i> , 2010, 18, 21-27.	1.0	31
461	Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 872-881.	0.6	12
462	Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review. <i>European Urology</i> , 2010, 58, 261-269.	0.9	73
463	Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. <i>Cancer</i> , 2010, 116, 2590-2595.	2.0	25
464	Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. <i>Prostate</i> , 2010, 70, 1395-1401.	1.2	26
465	Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. <i>BJU International</i> , 2010, 105, 1074-1081.	1.3	103
466	Management of prostate cancer in older adults. , 0, , 186-200.		0
467	The Prostate. , 2010, , 701-715.		0
469	The Scientific Basis of Urology. , 0, , .		18
470	Probleme der PSA-Bestimmung bei Älteren Patienten: was ist sinnvoll? / PSA measurements in elderly patients: what makes sense?. <i>Laboratoriums Medizin</i> , 2010, 34, 319-324.	0.1	0
471	A Phase II Trial of a Soy Beverage for Subjects Without Clinical Disease With Rising Prostate-Specific Antigen After Radical Radiation for Prostate Cancer. <i>Nutrition and Cancer</i> , 2010, 62, 198-207.	0.9	34
472	Angiogenesis inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 233-247.	0.9	34
473	Intermittent androgen suppression for prostate cancer. <i>Nature Reviews Urology</i> , 2010, 7, 552-560.	1.9	34

#	ARTICLE	IF	CITATIONS
474	Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment. <i>Pharmacology</i> , 2010, 85, 110-120.	0.9	35
475	New Developments in the Medical Management of Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2010, 85, 77-86.	1.4	70
476	An update on androgen deprivation therapy for prostate cancer. <i>Endocrine-Related Cancer</i> , 2010, 17, R305-R315.	1.6	147
477	Standard androgen deprivation therapy for prostate cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010, 7, 5-8.	0.5	1
478	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
479	Timing of first-line cancer treatments â€œ Early versus late â€œ A systematic review of phase III randomized trials. <i>Cancer Treatment Reviews</i> , 2010, 36, 621-628.	3.4	12
480	Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1075-1079.	1.0	19
481	The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis. <i>Urology</i> , 2010, 75, 1138-1143.	0.5	28
482	Antineoplastic effect of <i>âˆ—</i> -elemene on prostate cancer cells and other types of solid tumour cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1018-1027.	1.2	104
483	Tribulations of a prostate cancer trial â€œ Lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 508-511.	0.9	3
484	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010, 9, 675-691.	0.1	19
485	Long-Term Hormonal Therapy: Who Would Benefit?. <i>European Urology Supplements</i> , 2010, 9, 695-700.	0.1	1
486	The Evolution and Current Paradigm of Chemotherapy for Metastatic Castrate-Resistant Prostate Cancer. <i>British Journal of Medical and Surgical Urology</i> , 2011, 4, S2-S8.	0.2	2
487	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2011, 35, 565-579.	0.2	14
488	Pharmacotherapeutic Management of Locally Advanced Prostate Cancer. <i>Drugs</i> , 2011, 71, 1019-1041.	4.9	34
489	Traditional Approaches to Androgen Deprivation Therapy. <i>Urology</i> , 2011, 78, S485-S493.	0.5	5
490	Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 647-653.	0.8	93
491	Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 107.	1.0	14

#	ARTICLE	IF	CITATIONS
492	Quality of Care for Older Patients With Cancer in the Veterans Health Administration Versus the Private Sector. <i>Annals of Internal Medicine</i> , 2011, 154, 727.	2.0	84
493	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2011, 59, 572-583.	0.9	459
495	Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?. <i>Current Urology Reports</i> , 2011, 12, 188-196.	1.0	10
496	An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer. <i>Prostate Cancer</i> , 2011, 2011, 1-8.	0.4	7
497	Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. <i>ISRN Oncology</i> , 2012, 2012, 1-7.	2.1	12
498	Overview of Randomized Controlled Treatment Trials for Clinically Localized Prostate Cancer: Implications for Active Surveillance and the United States Preventative Task Force Report on Screening?. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 221-229.	0.9	16
499	The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 477-484.	0.6	31
500	Advanced prostate cancer: treatment and patient-centred care. <i>British Journal of Nursing</i> , 2012, 21, S24-S30.	0.3	1
501	An artificially constructed radiation-responsive promoter is activated by doxorubicin. <i>Cancer Gene Therapy</i> , 2012, 19, 345-351.	2.2	2
502	Reducing Bias in the Assessment of Treatment Effectiveness. <i>Medical Care</i> , 2012, 50, 374-380.	1.1	14
503	Who Should Receive Androgen Deprivation Therapy?. <i>European Urology</i> , 2012, 62, 973-974.	0.9	1
505	Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 37-43.	1.4	11
506	The multi-disciplinary management of high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 3-15.	0.8	19
507	Landmarks in hormonal therapy for prostate cancer. <i>BJU International</i> , 2012, 110, 23-29.	1.3	23
508	Germline Predictors of Androgen Deprivation Therapy Response in Advanced Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2012, 87, 240-246.	1.4	25
509	Treatment of Localized Prostate Cancer. , 2012, , 141-154.		0
510	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. <i>Asian Journal of Andrology</i> , 2012, 14, 177-186.	0.8	44
511	Endocrine prevention and treatment of prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 59-67.	1.6	23

#	ARTICLE	IF	CITATIONS
512	Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation. <i>Cancer</i> , 2012, 118, 5768-5776.	2.0	45
513	Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. <i>European Urology</i> , 2012, 61, 11-25.	0.9	206
514	The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?. <i>Medical Oncology</i> , 2013, 30, 647.	1.2	4
515	Imaging treated prostate cancer. <i>Abdominal Imaging</i> , 2013, 38, 1431-1446.	2.0	16
516	Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1205-1219.	0.9	30
517	Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. <i>Medical Oncology</i> , 2013, 30, 717.	1.2	13
518	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
520	Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer. <i>Drugs</i> , 2013, 73, 1517-1524.	4.9	5
521	Impact of Genetic Targets on Prostate Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 359-383.	0.8	2
522	Androgen and Androgen Receptor-Directed Therapy as Initial Treatment for Prostate Cancer. , 2013, , 861-871.		0
523	Targeting the RANKL Pathway: Putting the Brakes on Prostate Cancer Progression in Bone. <i>Journal of Clinical Oncology</i> , 2013, 31, 3838-3840.	0.8	7
524	Androgen deprivation treatment in prostate cancer. <i>BMJ, The</i> , 2013, 346, e8555-e8555.	3.0	13
525	Tumor Boards and the Quality of Cancer Care. <i>Journal of the National Cancer Institute</i> , 2013, 105, 113-121.	3.0	182
526	The Changing Natural History of Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 19-24.	1.0	37
527	Results of hormone therapy as first-line treatment for high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 355-359.	0.9	0
528	Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management. <i>ISRN Urology</i> , 2013, 2013, 1-8.	1.5	37
529	Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013010395-bcr2013010395.	0.2	4
530	Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy. <i>PLoS ONE</i> , 2014, 9, e105091.	1.1	4

#	ARTICLE	IF	CITATIONS
533	Androgen ablation for low-risk prostate cancer is common among male hip fracture patients. <i>Scandinavian Journal of Urology</i> , 2014, 48, 189-194.	0.6	5
534	The "Timing of Androgen-Deprivation therapy in incurable prostate cancer"™ protocol (TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial. <i>BJU International</i> , 2014, 114, 9-12.	1.3	4
535	Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1460.	2.6	75
536	Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mTOR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. <i>Targeted Oncology</i> , 2014, 9, 359-366.	1.7	7
537	Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. <i>Ageing Male</i> , 2014, 17, 87-93.	0.9	16
538	Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study. <i>European Journal of Cancer</i> , 2014, 50, 1789-1798.	1.3	17
539	Efficacy of tegafur"uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy. <i>International Urology and Nephrology</i> , 2014, 46, 1123-1129.	0.6	3
540	Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma. <i>World Journal of Urology</i> , 2014, 32, 661-667.	1.2	4
541	Concept and viability of androgen annihilation for advanced prostate cancer. <i>Cancer</i> , 2014, 120, 2628-2637.	2.0	16
542	Medical treatment for biochemical relapse after radiotherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 540-544.	0.6	3
543	Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. <i>Medical Oncology</i> , 2014, 31, 45.	1.2	6
544	Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population. <i>Medical Oncology</i> , 2014, 31, 979.	1.2	10
546	Racial Disparities in Cancer Care in the Veterans Affairs Health Care System and the Role of Site of Care. <i>American Journal of Public Health</i> , 2014, 104, S562-S571.	1.5	57
547	Risk of acute myocardial infarction after androgen"deprivation therapy for prostate cancer in a Chinese population. <i>BJU International</i> , 2015, 116, 382-387.	1.3	16
548	Hormones in cancer. , 0, , 24-41.		0
549	Diagnosis of prostate cancer via nanotechnological approach. <i>International Journal of Nanomedicine</i> , 2015, 10, 6555.	3.3	20
550	Management of Locally Advanced Prostate Cancer. , 2015, , 807-816.		0
552	Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?. <i>European Urology</i> , 2015, 68, 40-41.	0.9	0

#	ARTICLE	IF	CITATIONS
553	A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Japanese Journal of Clinical Oncology, 2015, 45, 197-201.	0.6	6
554	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. European Journal of Cancer, 2015, 51, 817-824.	1.3	56
555	The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment. Urology, 2015, 85, 1137-1142.	0.5	11
556	Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Japanese Journal of Clinical Oncology, 2015, 45, 483-487.	0.6	19
557	Developing and Evaluating Composite Measures of Cancer Care Quality. Medical Care, 2015, 53, 54-64.	1.1	10
558	Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. European Journal of Surgical Oncology, 2015, 41, 1529-1539.	0.5	18
560	Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology, 2016, 46, 1042-1046.	0.6	13
562	The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nature Reviews Urology, 2016, 13, 353-364.	1.9	22
563	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06) The, 2016, 17, 727-737.	5.1	172
564	Neuronal Transdifferentiation in Prostate Cancer Cells. Prostate, 2016, 76, 1312-1325.	1.2	27
565	Oligometastatic Prostate Cancer. Current Treatment Options in Oncology, 2016, 17, 62.	1.3	19
566	Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. , 2016, , 481-489.		0
568	Management of Prostate Cancer in the Elderly. Clinics in Geriatric Medicine, 2016, 32, 113-132.	1.0	12
569	Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer. , 2016, , 2467-2484.e5.		0
571	Androgen deprivation in prostate cancer: first do no harm. Lancet Oncology, The, 2017, 18, 1142-1144.	5.1	3
572	Prostatic Tumors. , 2017, , 95-167.		0
574	Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer – a phase III study (PRINCE). BJU International, 2018, 122, 774-782.	1.3	10
575	Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?. European Urology, 2018, 73, 519-520.	0.9	5

#	ARTICLE	IF	CITATIONS
576	Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective. <i>International Urology and Nephrology</i> , 2018, 50, 665-673.	0.6	3
577	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 834-841.	1.6	7
578	Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. <i>Targeted Oncology</i> , 2018, 13, 679-689.	1.7	15
579	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018, 1, 238-241.	2.6	25
580	Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2019, 2019, CD003506.	1.5	10
581	Targeting Angiogenesis in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2676.	1.8	94
582	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or enzalutamide. <i>Cancer</i> , 2019, 125, 1777-1788.	2.0	50
583	Effective and well tolerated: where do these drugs fit now?. <i>Lancet Oncology</i> , 2019, 20, 469-470.	5.1	0
584	A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e203-e208.	0.9	6
585	Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression. <i>World Journal of Urology</i> , 2019, 37, 2137-2145.	1.2	11
586	Oligometastatic prostate cancer: Reality or figment of imagination?. <i>Cancer</i> , 2019, 125, 340-352.	2.0	72
588	Biomarkers for prostate cancer: prostate-specific antigen and beyond. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 326-339.	1.4	123
589	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	0.8	7
590	Indications and Complications of Androgen Deprivation Therapy. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151042.	0.7	3
591	Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 701-707.	0.2	2
592	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	0.8	8
593	Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. <i>Prostate</i> , 2020, 80, 824-830.	1.2	11
594	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , 2020, 80, 527-544.	1.2	34

#	ARTICLE	IF	CITATIONS
595	The Impact of Geographic Location on Saskatchewan Prostate Cancer Patient Treatment Choices: A Multilevel and Spatial Analysis. <i>Journal of Rural Health</i> , 2020, 36, 564-576.	1.6	2
596	Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e739-e753.	0.9	26
597	Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group. <i>International Journal of Clinical Practice</i> , 2021, 75, e14095.	0.8	6
598	Androgen deprivation therapy and acute kidney injury in prostate cancer: room for debate?. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 933-934.	2.0	2
599	The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. <i>Cancer</i> , 2000, 88, 2989-2994.	2.0	7
600	Hormone therapy for patients with prostate carcinoma. <i>Cancer</i> , 2000, 88, 3009-3014.	2.0	1
602	Clinical Progression to Castration-Recurrent Prostate Cancer. , 2009, , 57-72.		1
603	Locally Invasive Prostate Cancer. , 2000, , 223-243.		1
604	Management of Recurrent Disease After Definitive Therapy. , 2000, , 245-263.		1
605	Trends in Prostate Cancer Screening: Canada. , 2009, , 23-33.		2
606	Androgen Deprivation Therapy. , 2010, , 101-107.		2
607	Endocrine Manipulation. , 2008, , 518-535.		4
608	The Role of Hormonal Treatment in Prostate Cancer. , 2007, 175, 211-237.		18
609	Guidelines and Counselling for Treatment Options in the Management of Prostate Cancer. , 2007, 175, 131-162.		4
610	Prostatakarzinom. , 2013, , 723-744.		1
612	Endocrinology of the Prostate. , 2010, , 2592-2609.		2
613	Cancer of the Prostate. , 2010, , 925-986.		2
614	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2

#	ARTICLE	IF	CITATIONS
615	Hormone Therapy for Prostate Cancer. , 2012, , 2934-2953.e7.		10
617	Análisis de supervivencia de los pacientes con cáncer de próstata con factores patológicos desfavorables tratados con prostatectomía radical y radioterapia de rescate tras la recidiva y persistencia bioquímica. Actas Urológicas Españolas, 2020, 44, 701-707.	0.3	3
619	Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. BJU International, 1999, 83, 18-33.	1.3	32
620	Advances in prostate cancer. Current Opinion in Oncology, 1999, 11, 226.	1.1	15
621	PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER. Journal of Urology, 2000, , 1632-1642.	0.2	15
622	QUALITY OF LIFE OF ASYMPTOMATIC MEN WITH NONMETASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY. Journal of Urology, 2000, , 1743-1746.	0.2	7
623	ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2001, , 2208-2215.	0.2	7
624	Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2002, , 1952-1956.	0.2	86
625	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer:. Journal of Urology, 2002, , 429-435.	0.2	14
626	Hormone Therapy for Locally Advanced Prostate Cancer. Journal of Urology, 2002, , 546-549.	0.2	5
627	Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer. Journal of Urology, 2002, , 1005-1007.	0.2	9
628	Controversy in managing patients with prostate cancer. BMJ: British Medical Journal, 1998, 316, 1919-1920.	2.4	12
629	Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget, 2016, 7, 8389-8398.	0.8	34
630	The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy. Central European Journal of Urology, 2011, 64, 218-222.	0.2	2
631	Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update. Archives of Pathology and Laboratory Medicine, 2009, 133, 1033-1040.	1.2	44
632	Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7123-7127.	0.5	3
633	Hormonal Manipulation of Prostate Cancer. , 2000, , 293-311.		0
634	Hormonal Therapy. , 2000, , 265-288.		0

#	ARTICLE	IF	CITATIONS
636	Prostatakarzinom. , 2001, , 371-394.		0
638	RE: A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER???EVIDENCE FOR DEFERRED TREATMENT. Journal of Urology, 2002, , 653.	0.2	2
641	Management of Metastatic Prostate Cancer. , 2003, , 185-199.		0
642	Neurologic Complications of Genitourinary Malignancies. , 2003, , 327-338.		1
643	Management of PSA Recurrence After Definitive Therapy for Prostate Cancer. , 2004, , 525-551.		0
644	Prostatakarzinom. , 2004, , 1233-1266.		0
645	Management of Newly Diagnosed Metastatic Disease. , 2004, , 561-578.		0
646	Tumour suppressor genes and oncogenes. , 2004, , 411-422.		0
647	Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy. , 2004, , 307-338.		0
648	Novel Therapies for PSA Progression in the Absence of Imagable Disease Following Local Therapy. , 2004, , 339-366.		0
649	Which patients with prostate cancer are actually candidates for hormone therapy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2004, 30, 455-465.	0.7	3
650	Progressive Bone Loss due to Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2005, 31, 203-210.	0.0	0
651	Prostatakarzinom. , 2006, , 5019-5061.		0
654	Liver metastases. , 2007, , 263-272.		0
656	An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer. , 2009, , 1-13.		0
657	Hormonal Therapy in the Elderly Prostate Cancer Patient. Deutsches Ärztblatt International, 2009, 106, 242-7.	0.6	6
659	Update on the management of prostate cancer with goserelin acetate: patient perspectives. Cancer Management and Research, 2009, 1, 99.	0.9	0
661	Hormonal Therapy in Cancer. , 2011, , 165-190.		0

#	ARTICLE	IF	CITATIONS
662	Treatment of Locally Advanced Prostate Cancer. , 2012, , 2903-2920.e5.		5
663	Management of Newly Diagnosed Metastatic Disease. , 2012, , 361-378.		0
665	RADICAL RETROPUBIC PROSTATECTOMY PLUS ORCHIECTOMY VERSUS ORCHIECTOMY ALONE FOR pTxN+ PROSTATE CANCER. Journal of Urology, 1999, , 1227.	0.2	0
666	Association of Time to PSA Nadir and Logarithm of PSA Velocity After Progression in Metastatic Prostate Cancer with Prior Primary Androgen Deprivation Therapy. Asian Journal of Andrology, 2015, 19, 98-102.	0.8	8
667	Bone Metastases from Prostate Cancer: Hormonal Therapy. , 2017, , 105-120.		0
668	First-Line Hormonal Manipulation: Surgical and Medical Castration with LHRH Agonists and Antagonists, Steroids, and Pure Antiandrogens. , 2017, , 313-325.		0
669	Hormonale therapie. , 2017, , 119-158.		0
670	Androgen Deprivation Therapy for Clinically Localized Prostate Cancer. , 2018, , 121-131.		0
674	The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer. , 2008, , 339-354.		0
675	Prostatakarzinom. , 0, , 1051-1078.		0
676	Hormonal therapy in prostate cancer: historical approaches. Reviews in Urology, 2004, 6 Suppl 7, S3-S11.	0.9	12
677	Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Reviews in Urology, 2001, 3, 72-84.	0.9	23
678	Androgen deprivation and other treatments for advanced prostate cancer. Reviews in Urology, 2001, 3 Suppl 2, S59-68.	0.9	3
679	The effective management of biochemical recurrence in patients with prostate cancer. Reviews in Urology, 2005, 7 Suppl 5, S29-36.	0.9	6
680	Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Reviews in Urology, 2003, 5 Suppl 2, S3-S13.	0.9	3
681	Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Reviews in Urology, 2003, 5 Suppl 3, S3-S13.	0.9	1
682	Advanced prostate cancer: an update. Reviews in Urology, 2000, 2 Suppl 4, S35-9.	0.9	0
683	Hormonal therapy for prostate cancer. Reviews in Urology, 2006, 8 Suppl 2, S35-47.	0.9	14

#	ARTICLE	IF	CITATIONS
684	Approach to primary care follow-up of patients with prostate cancer. Canadian Family Physician, 2008, 54, 204-10.	0.1	5
685	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clinical Advances in Hematology and Oncology, 2013, 11, 14-23.	0.3	119
686	Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. Neurosurgery, 2022, 90, 743-749.	0.6	6
687	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. Cancers, 2022, 14, 1803.	1.7	5
688	Trends in Prostate Cancer Incidence and Mortality. , 0, , 246-257.		1
689	Genitourinary Cancer. , 0, , 309-334.		0
691	WHICH PATIENTS SHOULD RECEIVE RADIOTHERAPY IN POSTOPERATIVE DISEASE RECURRENCE?. Acta Clinica Croatica, 2019, 58, 42-45.	0.1	2
693	How can we best manage biochemical failure after radical prostatectomy?. Investigative and Clinical Urology, 2022, 63, 592.	1.0	1
695	Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. Advances in Radiation Oncology, 2023, 8, 101066.	0.6	0
696	Testosterone Therapy in Advanced Prostate Cancer. Androgens: Clinical Research and Therapeutics, 2022, 3, 180-186.	0.2	0